New tools. Same assumptions underneath.
Recruitment keeps adding tools: more reach, more sites, health-record mining, now AI. None of them change how many patients clear your protocol. A Market Feasibility Test (MFT) measures that qualification rate against real patients before clinical research sites open, while the protocol can still change.
In one Parkinson's MFT, 214 patients came forward and 9 qualified. Every one of the nine wanted contact about a local study. Interest was high. A narrow device-history rule set the ceiling. More reach and more sites would screen the same 214 to the same 9. (Antidote’s Parkinson’s MFT, n=214, 2025)
What's inside the brief:
- Why the tool-swapping reflex persists
- What untested assumptions cost sponsors, in timeline and budget
- How an MFT reveals the qualification rate before launch, across five case studies
Download the brief.
